Published May 31, 2017 | Version v1
Journal article Open

Induction of immune gene expression and inflammatory mediator release by commonly used surgical suture materials: an experimental in vitro study

  • 1. Department of Medicine, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
  • 2. Department of Orthopaedics, Middlemore Hospital, Private Bag 93311, Auckland, New Zealand

Description

Background: Surgeons have a range of materials to choose from to complete wound closure, yet surprisingly very little is still known about the body's immune response to the suture materials in current use. The growing literature of adverse suture material reactions provided the objective of this study, to use in vitro assays to quantify levels of inflammation produced by seven commonly used suture materials in surgical procedures.

Methods: Human monocyte/macrophage THP-1 cells were exposed to suture materials for 1, 3 and 5 days. Gene expression and protein secretion of six inflammatory cytokines and two cell surface markers were assessed using qPCR and ELISA respectively, with LPS exposure providing a positive control. Furthermore, a IL-1β/IL-1RA marker ratio was assessed to determine the balance between pro-/anti-inflammatory expression.

Results: The findings from our in vitro study suggest that four commonly used suture materials cause upregulation of pro-inflammatory markers indicative of an early foreign body reaction, with no balance from anti-inflammatory markers.

Conclusions: As prolonged early pro-inflammation is known to produce delayed wound healing responses, the knowledge produced from this study has potential to improve informed surgical decision making and patient safety. This work has the capability to reduce suture-related adverse immune reactions, and therefore positively affect patient outcomes.

Files

13037_2017_Article_132.pdf

Files (926.9 kB)

Name Size Download all
md5:bc143a633b5c8efd30f4783ac231a24a
906.9 kB Preview Download
md5:f8a90dda1444ab48758774cc50843399
20.0 kB Download

Additional details

Funding

SKELGEN – Establishment of a cross continent consortium for enhancing regenerative medicine in skeletal tissues 318553
European Commission